Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating ...

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect

Atea Pharmaceuticals Doses First Patient in Phase 3 Trial for Chronic Hepatitis C

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, to another HCV combination regimen.